- Overview of Curis, including key partnerships, balance sheet, and recent stock price.
- Review of Non-Hodgkin’s Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, current key therapies, and market size of some of the larger therapies in the space.
- Overview of molecule CA-4948 including recent clinical results and potential importance of IRAK-4 inhibition.
- An initialhigh-level estimate of potential revenue for CA-4948 is provided usingImbruvica as an analog as Curis believes that CA-4948 could be used in combinationwith Imbruvica for Non-Hodgkin’s Lymphoma.
- Thoughts on valuation and investment potential.
For further details see:
Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition